Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
Menée sur une cohorte en population de 186 patients atteints d'un lymphome à cellules du manteau, cettte étude évalue l'intérêt de mesurer l'expression de SOX11 pour diagnostiquer une forme indolente de la maladie
The prognostic role of the transcription factor SOX11 in MCL is controversial. We investigated prognostic markers in a population-based cohort of 186 MCL cases. Seventeen patients (9%) did not require any therapy within the first 2 years after diagnosis and were retrospectively defined as having an indolent disease. As expected, indolent MCL had less frequently B symptoms and extensive nodal involvement and 88% of these cases expressed SOX11. In our cohort 13 cases (7,5%) lacked nuclear SOX11 at diagnosis. SOX11 negative MCL had a higher frequency of lymphocytosis, elevated LDH and p53 positivity. The overall survival in the whole cohort, excluding 37 patients receiving ASCT, was 3,1 years and in patients with indolent or non-indolent disease, 5,9 and 2,8 years, respectively (p=0,004). SOX11 negative cases had a shorter overall survival, compared to SOX11 positive cases; 1,5 and 3,2 years, respectively (p=0,014). In multivariate analysis of overall survival, age>65 (p=0,001), ECOG≥2 (p=0,022), elevated LDH (p=0,001) and p53 expression (p=0,001) remained significant while SOX11 lost significance. We conclude that most indolent MCL are SOX11 positive and that SOX11 cannot be used for predicting an indolent disease course.
Blood , résumé, 2012